AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04532346 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine
Description: Hydroxychloroquine Sulfate is an anti-malarial and anti-rheumatic drug. hydroxychloroquine has been reported to improve the clinical status of chILD cases wtih genetic causes. The exact mechanism of action of hydroxychloroquine is unknown. In additon to having anti-inflammatory properties, hydroxychloroquine has been shown to affect intracellular processing of surfactant protein.
Study NCT05223998 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Full-thickness skin microcolumns implantation
Description: Surgical harvest and implantation of FTSM on an open wound requiring coverage.
Study NCT05644717 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ertugliflozin 5 mg, 15mg
Description: Ertugliflozin 5/15mg once daily in addition to standard of care
Study NCT05238519 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational interview (MI)
Description: The MI intervention is adapted from the CHEERS study intervention (M Health Fairview) found to be effective in promoting lipid screening in patients at increased risk for FH.~Within one month of completion of the baseline survey, a study coordinator, who received training in motivational interview integrity, will conduct a 20-40-minute (depending on participant needs) telephone or virtual (zoom) interview with participants randomized to this arm. Participants will be assessed on their readiness to get their cholesterol checked and discuss with family members the risk of FH.
Study NCT05309967 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: GLUMA DESINSITIZER
Description: GLUTARALDEHYDE
Study NCT05309967 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: PLACEBO
Description: DESTILLED WATER
Study NCT05593315 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Mindfulness and Buteyko techniques
Description: Joint implementation of a general relaxation program and a respiratory rehabilitation program in patients with poorly controlled asthma.
Study NCT05749367 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine + saline solution
Description: SIFIB with 30 ml of 0.5% ropivacaine and PENG Block plus LFCNB with 20 ml and 10 ml of saline solution, respectively.
Study NCT05749367 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saline solution + Ropivacaine
Description: SIFIB with 30 ml of saline solution and PENG Block plus LFCNB with 20 ml and 10 ml of 0,5% ropivacaine, respectively.
Study NCT05656287 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SMS texts + incentives + Wisepill device for medication monitoring
Description: For the first two months, 54 participants will receive i) daily SMS medication reminders, ii) monthly mobile money for transport to the clinic, and iii) monthly mobile money incentives if >90% medication adherence. For the remaining four months, the participants will receive: i) weekly medication SMS reminders, ii) monthly mobile money for transport to the clinic, iv) monthly mobile money incentives if >90% medication adherence.
Study NCT03698448 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: OligoG Dry powder for inhalation
Description: 10 capsules Dry Powder for Inhalation, BID
Study NCT06469190 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KN5501
Description: Patients will receive Fludarabine (30 mg/m2 per day) and Cyclophosphamide (300mg/m2 per day) on day -5, -4, and -3. Multiple doses of anti-CD19 CAR NK cells (KN5501) will infused in each group using the 3 + 3 dose-escalation strategy.
Study NCT05978674 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: rocking bed group
Description: Babies assigned to the intervention group first will be placed on a rocking bed after routine care such as feeding and diaper changes and when the newborn is stable. A rocking attempt will be applied to the baby placed in the rocking bed for 30 minutes. After 30 minutes, the baby will not be lifted from the bed and will lie in bed for 90 minutes. After a period of two hours in total, the babies will be cared for and fed. Then, babies will be quota and control group measurements will be made.
Study NCT05409703 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: reiki therapy
Description: reiki therapy for nurses
Study NCT06536543 — intervention group
Intervention type: OTHER
Intervention: Acute Respiratory Distress Syndrom (ARDS) treated with Prone Position (PP) equipped with Electrical Impedance Tomography (EIT)
Description: Positive End-Expiratory Pressure (PEEP) will be titrated with PEEP-EIT method as it is already done in usual care. A classical low flow Pression Volume (PV) curve will be done in order to detect airway closure and measure compliance, the acquisition of EIT data during PV curve will be analysed secondary with a dedicated software. Reconstruction of EIT derived PV curve will determine the regional airway opening pressures and compliances of the 2 lungs. Two decremental PEEP-EIT titrations will be compared, one in supine and the other just after turning in prone.
Study NCT06712706 — intervention group
Intervention type: PROCEDURE
Intervention: Feeding jejunostomy placement
Description: Placement of feeding jejunostomy at staging laparoscopy
Study NCT06712706 — intervention group
Intervention type: PROCEDURE
Intervention: Feeding jejunostomy placement at esophagectomy
Description: Placement of feeding jejunostomy at esophagectomy
Study NCT05874505 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adalimumab
Description: Adalimumab 80 mg at Day 0 then 40 mg subcutaneous at week 1, 3, 5, 7, 9, 11, 13 and 15
Study NCT05874505 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Description: Tocilizumab 162 mg subcutaneous each week for 15 weeks
Study NCT04750343 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GBP510 adjuvanted with AS03 (RBD 10μg/dose) - Stage 1
Description: Participants will receive intramuscular (IM) injections of GBP510 adjuvanted with AS03 (RBD 10μg/dose) on Days 0 and 28.
Study NCT04750343 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GBP510 (RBD 10μg/dose) - Stage 1
Description: Participants will receive intramuscular (IM) injections of GBP510 (RBD 10μg/dose) on Days 0 and 28.
Study NCT04750343 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline (0.9% sodium chloride solution) - Stage 1
Description: Participants will receive intramuscular (IM) injections of Normal saline on Days 0 and 28.
Study NCT04750343 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GBP510 adjuvanted with AS03 (RBD 25μg/dose) - Stage 1
Description: Participants will receive intramuscular (IM) injections of GBP510 adjuvanted with AS03 (RBD 25μg/dose) on Days 0 and 28.
Study NCT04750343 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GBP510 (RBD 25μg/dose) - Stage 1
Description: Participants will receive intramuscular (IM) injections of GBP510 (RBD 25μg/dose) on Days 0 and 28.
Study NCT04750343 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GBP510 adjuvanted with AS03 (RBD 10μg/dose) - Stage 2
Description: Participants will receive intramuscular (IM) injections of GBP510 adjuvanted with AS03 (RBD 10μg/dose) on Days 0 and 28.
Study NCT04750343 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GBP510 adjuvanted with AS03 (RBD 25μg/dose)- Stage 2
Description: Participants will receive intramuscular (IM) injections of GBP510 adjuvanted with AS03 (RBD 25μg/dose) on Days 0 and 28.
Study NCT04750343 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GBP510 (RBD 25μg/dose)- Stage 2
Description: Participants will receive intramuscular (IM) injections of GBP510 (RBD 25μg/dose) on Days 0 and 28.
Study NCT04750343 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline (0.9% sodium chloride solution)- Stage 2
Description: Participants will receive intramuscular (IM) injections of Normal saline on Days 0 and 28.
Study NCT04219449 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: PT
Description: measuring PT drawn on citrated blood sample
Study NCT04219449 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Protein C
Description: measuring protein C drawn on citrated blood sample
Study NCT04219449 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Platelet aggregation by ADP and arachidonic acid
Description: measuring platelet aggregation drawn on citrated blood sample
Study NCT05591755 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brimonidine Tartrate 0.025%/ Ketotifen Fumarate 0.035% Ophthalmic Solution
Description: Brimonidine Tartrate 0.025%/ Ketotifen Fumarate 0.035% Ophthalmic Solution
Study NCT05591755 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketotifen fumarate ophthalmic solution 0.035% (n = 56)
Description: Ketotifen fumarate ophthalmic solution 0.035% (n = 56)
Study NCT05591755 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brimonidine tartrate ophthalmic solution 0.025% (n = 56)
Description: Brimonidine tartrate ophthalmic solution 0.025% (n = 56)
Study NCT05591755 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Experimental: Vehicle ophthalmic solution (n = 56)
Description: Experimental: Vehicle ophthalmic solution (n = 56)
Study NCT06220149 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: FIT (fecal immunochemical test)
Description: A FIT (fecal immunochemical test) will be done daily for the 14 days following polypectomy.
Study NCT06257680 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ReT01 ACT
Description: Patients were infused with ReT01 ACT injection after pretreatment, and subjects were closely observed for 24 hours after each infusion.
Study NCT05656287 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SMS texts only + Wisepill device for medication monitoring
Description: For the first 2 months, 54 participants will receive daily SMS medication reminders, ii). For the remaining 4 months, the participants will receive weekly medication SMS reminders. All participants will also receive a Wisepill device for medication monitoring.
Study NCT05656287 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Wisepill device for medication monitoring only
Description: Participants (54) in the Control arm will not receive SMS reminders or mobile money. All participants will also receive a Wisepill device for medication monitoring.
Study NCT04562532 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Microport Firehawk stent
Description: MicroPort Firehawk biodegradable polymer rapamycin target eluting stent
Study NCT04562532 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 2nd generation DES (XIENCE family, Promus family, Resolute/Onyx family/Endeavor, and Orsiro stent)
Description: * Everolimus eluting stents (Xience family - Abbott Vascular, Promus family- Boston Scientific, Synergy - Boston Scientific)~* Zotarolimus eluting stents (Resolute/Onyx family and Endeavor- Medtronic)~* Sirolimus eluting stents (Orsiro- Biotronik)
Study NCT05586815 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Colistin
Description: 150 mg every 8 hours intravenously for at least 7 and up to a maximum of 28 days
Study NCT05586815 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Colistin
Description: 150 mg every 8 hours intravenously for at least 7 and up to a maximum of 28 days
Study NCT05586815 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Minocycline
Description: 200 mg every 12 hours orally for at least 7 and up to a maximum of 28 days
Study NCT05586815 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Capsule without active compound
Study NCT03698448 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: OligoG Dry powder for inhalation
Description: 10 capsules Dry Powder for Inhalation, BID
Study NCT05344248 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: JS005 (recombinant humanized monoclonal antibody against IL-17A)
Description: Subcutaneous injection
Study NCT05344248 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: JS005 placebo
Description: Subcutaneous injection
Study NCT06420999 — intervention group
Intervention type: OTHER
Intervention: Diaphragmatic ultrasound and data collection
Description: At the inclusion visit, anamnestic data available in the medical record and clinical data (vitals, chest X-ray) will be collected. At the same time, a diaphragmatic ultrasound will be performed in the half-seated position to measure diaphragmatic excursion and the thickening fraction of the right hemi-diaphragm at rest. A follow-up visit will be made on the day of discharge from intensive care, during which diaphragmatic ultrasound will be performed At D90 (+/- 15 days), the following information will be collected by consulting the electronic medical record, or by telephone if the information is not available in the record: date of discharge from hospital, date of death, date and reason for readmission to hospital or intensive care, possible introduction of long-term non-invasive ventilation, new respiratory complication after discharge from intensive care (pneumonia, atelectasis).
Study NCT05687981 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: the use of higher concentration of bupivacaine in ilioinguinal and iliohypogastric nerve block (IINB) might increase the efficacy of postoperative analgesia
Study NCT05687981 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: 2 mg dexamethasone
Study NCT05941663 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Dental implant surface
Description: Implants provided were Bone Level Tapered (Bone Level Tapered) Roxolid® implants with a SLActive® or SLActive® surface
Study NCT05941663 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dental implant surface
Description: Implants provided were Bone Level Tapered (Bone Level Tapered) Roxolid® implants with a SLActive® or SLActive® surface
Study NCT04879784 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study NCT05157711 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anusol
Description: Daily at night and in the morning and after each bowel movement for two weeks
Study NCT05157711 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Relief [Name]
Description: Daily at night and in the morning and after each bowel movement for two weeks
Study NCT05157711 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Daily at night and in the morning and after each bowel movement for two weeks
Study NCT05813314 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: BMN 111 administration via Injector Pen
Description: BMN 111 Injection will be given using an injector pen
Study NCT05813314 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BMN 111 administration via vial and syringe
Description: BMN 111 Injection will be given using vial and syringe
Study NCT05738759 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epidural Anesthetic Cocktail
Description: The anesthetic cocktail, consists of triamcinolone 40 mg, marcaine 5 mg, and morphine 3 mg, is soaked in the gelfoam size 1x2 cm and applied on the epidura before removal of the endoscope.
Study NCT05738759 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo is soaked with NSS in the gelfoam size 1x2 cm as well and applied on the epidura before removal of the endoscope.
Study NCT04974866 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EGFR-TK Inhibitor
Description: epidermal growth factor receptor tyrosine kinase inhibitors
Study NCT05748613 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Computerized Anxiety Sensitivity Treatment
Description: Brief computerized treatment for anxiety sensitivity
Study NCT05748613 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Health Education Control
Description: Brief computerized presentation on healthy behaviors
Study NCT06289153 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Arthrex Internal Brace
Description: The Arthrex Internal Brace method for ACL reconstruction consists of suture tape used to reinforce the ACL during surgery. This suture tape is secured in place with bioabsorbable anchors that gradually degrade within the body over time.
Study NCT06289153 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ACL Reconstruction
Description: All patients will undergo ACL reconstruction (ACLR) with or without an internal brace.
Study NCT06383078 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: HR070803
Description: HR070803 60 mg/\^2 D1 over 90 minutes.
Study NCT06383078 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HR070803
Description: HR070803 60 mg/\^2 D1 over 90 minutes.
Study NCT06383078 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxaliplatin
Description: Oxaliplatin 85 mg/\^2 D1 over 2 hours.
Study NCT06383078 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Oxaliplatin 85 mg/\^2 D1 over 2 hours.
Study NCT06383078 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tegafur
Description: initial dose of S-1 is determined according to the body surface area，orally, D1-7.
Study NCT06383078 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Folinic acid
Description: Folinic acid 400 mg/\^2 D1
Study NCT06383078 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5-Fluorouracil
Description: 5-FU 2400 mg/\^2 D1 IV continuous infusion over 46 hours
Study NCT04524910 — intervention group
Intervention type: DRUG
Intervention: Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)
Description: As prescribed by the treating physician
Study NCT04911881 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IBI321
Description: Several dose levels will be evaluated for IBI321 administered as a single agent. IBI321 will be given via IV infusion on Day 1 of each cycle until disease progression or loss of clinical benefit.
Study NCT04022850 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: A non-reflective decision assistance strategy
Description: A strategy based on providing evidence-based information communication technology tools to help and guide decision-making: pop-up reminders and alerts with associated messages incorporated into the REGICOR CVR calculator in OSABIDE (Osakidetza's EHR system) and within the prescription pathway in PRESBIDE (the electronic drug prescribing component).
Study NCT04022850 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: A non-reflective decision assistance strategy
Description: A strategy based on providing evidence-based information communication technology tools to help and guide decision-making: pop-up reminders and alerts with associated messages incorporated into the REGICOR CVR calculator in OSABIDE (Osakidetza's EHR system) and within the prescription pathway in PRESBIDE (the electronic drug prescribing component).
Study NCT06289153 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ACL Reconstruction
Description: All patients will undergo ACL reconstruction (ACLR) with or without an internal brace.
Study NCT06303037 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remimazolam besylate and low-dose Esketamine
Description: Esketamine was injected intravenously 0.25mg/kg and the initial dose of Remimazolam was 0.3mg/kg
Study NCT06303037 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remimazolam besylate and Medium dose Esketamine
Description: Esketamine was injected intravenously 0.5mg/kg and the initial dose of Remimazolam was 0.2mg/kg
Study NCT05944601 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual and computer-based cognitive remediation training
Description: Amyloid-positive MCI patients, and individuals carrying the ApoE- ε4 allele will undergo a combined intervention of computer-based sessions of a spatial memory task by the Erica software (Giunti, Florence, Italy) and VR navigation sessions by the NeuroVirtual 3D software (Serino et al., 2010), in order to improve spatial memory for landmarks location and mental frame syncing for supporting spatial scenarios, respectively. The intervention will last one month for a total of 12 sessions (3 days a week, 50 minutes per session).
Study NCT06506162 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Flavor
Description: The study will compare sweet vs. cool flavors
Study NCT05190978 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Acellular Dermal Matrix
Description: Acellular dermal matrix will surgically implanted around the tissue expanders in patients in the ADM cohort.
Study NCT05190978 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Reconstruction without ADM
Description: Acellular dermal matrix will not be surgically implanted around the tissue expanders in patients in the control cohort.
Study NCT05115370 — intervention group
Intervention type: OTHER
Intervention: Semi-structured qualitative interview
Description: A single semi-structured qualitative interview conducted face-to-face or by telephone or video-conference call.
Study NCT05071612 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AD109
Description: Oral administration at bedtime
Study NCT05071612 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AD504
Description: Oral administration at bedtime
Study NCT05071612 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atomoxetine Hydrochloride
Description: Oral administration at bedtime
Study NCT05071612 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral administration at bedtime